Natixis Advisors, L.P. Supernus Pharmaceuticals, Inc. Transaction History

Natixis Advisors, L.P.

$51.3 Billion
Q3 2024

A detailed history of Natixis Advisors, L.P. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 39,318 shares of SUPN stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,318

Previous 34,205 14.95%

Holding current value

$1.42 Million

Previous $915,000 33.99%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$25.77 - $35.16 $131,762 - $179,773	5,113 Added 14.95%	39,318 $1.23 Million
Q2 2024 Aug 01, 2024	SELL	$25.99 - $33.85 $95,539 - $124,432	-3,676 Reduced 9.7%	34,205 $915,000
Q1 2024 Apr 25, 2024	BUY	$27.11 - $35.17 $30,417 - $39,460	1,122 Added 3.05%	37,881 $1.29 Million
Q4 2023 Feb 06, 2024	BUY	$22.72 - $29.68 $24,560 - $32,084	1,081 Added 3.03%	36,759 $1.06 Million
Q3 2023 Nov 13, 2023	BUY	$27.57 - $32.91 $45,407 - $54,202	1,647 Added 4.84%	35,678 $984,000
Q2 2023 Aug 15, 2023	SELL	$29.91 - $38.73 $81,145 - $105,074	-2,713 Reduced 7.38%	34,031 $1.02 Million
Q1 2023 May 11, 2023	BUY	$34.93 - $42.03 $41,706 - $50,183	1,194 Added 3.36%	36,744 $1.33 Million
Q4 2022 Jan 27, 2023	BUY	$31.09 - $37.88 $23,472 - $28,599	755 Added 2.17%	35,550 $1.27 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $43,098 - $53,008	1,497 Added 4.5%	34,795 $1.18 Million
Q2 2022 Aug 12, 2022	BUY	$25.33 - $34.25 $55,016 - $74,391	2,172 Added 6.98%	33,298 $963,000
Q1 2022 May 12, 2022	BUY	$28.51 - $32.9 $117,717 - $135,844	4,129 Added 15.29%	31,126 $1.01 Million
Q4 2021 Feb 08, 2022	BUY	$26.37 - $34.22 $130,610 - $169,491	4,953 Added 22.47%	26,997 $787,000
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $56,943 - $75,932	2,419 Added 12.33%	22,044 $588,000
Q2 2021 Aug 12, 2021	BUY	$26.72 - $33.19 $94,188 - $116,994	3,525 Added 21.89%	19,625 $604,000
Q1 2021 May 05, 2021	SELL	$24.15 - $31.45 $2,318 - $3,019	-96 Reduced 0.59%	16,100 $421,000
Q4 2020 Feb 12, 2021	BUY	$17.7 - $25.81 $66,799 - $97,406	3,774 Added 30.38%	16,196 $407,000
Q3 2020 Nov 12, 2020	SELL	$20.2 - $25.05 $32,784 - $40,656	-1,623 Reduced 11.56%	12,422 $259,000
Q2 2020 Aug 11, 2020	BUY	$17.09 - $24.89 $240,029 - $349,580	14,045 New	14,045 $334,000
Q1 2020 Apr 27, 2020	SELL	$14.45 - $24.69 $753,596 - $1.29 Million	-52,152 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$19.93 - $29.13 $254,964 - $372,660	-12,793 Reduced 19.7%	52,152 $1.24 Million
Q3 2019 Nov 12, 2019	SELL	$25.47 - $33.37 $380,318 - $498,280	-14,932 Reduced 18.69%	64,945 $1.79 Million
Q2 2019 Aug 12, 2019	BUY	$29.96 - $38.87 $2.39 Million - $3.1 Million	79,877 New	79,877 $2.64 Million

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Supernus Pharmaceuticals, Inc. Transaction History